Penumbra catheter recall
This article was originally published in The Gray Sheet
Firm is recalling older revisions of its Neuron 6F 070 delivery catheter after receiving reports that it could kink or ovalize in certain anatomy, leading to difficulty advancing the catheter or using it to deliver other devices. Consumers with the older Neuron 6F catheters should return them to receive a replacement, Penumbra says Sept. 29. In May, Penumbra recalled nine Neuron 5F Select catheters in a Class 1 action related to pinholes and exposed wire braids (1"The Gray Sheet" Sept. 14, 2009)
You may also be interested in...
Electro-shock comments: FDA will accept public comments through Jan. 8 on electro-shock therapy devices in response to a "significant number of inquiries from members of the public and the health care community," the agency says. Electroconvulsive therapy systems are among the 27 device types available prior to the 1976 Medical Device Amendments, for which new versions can reach the market via 510(k) clearance, though they have not been formally risk-classified by FDA. The agency ordered makers of ECT devices and 24 other product types to submit safety and effectiveness information by Aug. 7 to inform FDA's decision on whether to down-classify the products to Class I or II, or require PMA applications (1"The Gray Sheet" Aug. 17, 2009). The new docket allows individuals other than manufacturers to submit information on the safety and efficacy of ECT devices. FDA did not specify the source of the inquiries leading to the comment opening, but there has been substantial debate among the psychiatric establishment, which generally supports 510(k) access for ECT devices, and skeptic groups, such as the Committee on Truth in Psychiatry, an organization of former shock therapy patients who push for more substantial regulation
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.